Abstracts tagged "outcomes"

Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Marilia Dagostin¹, Sergio Nunes ², Samuel Shinjo ³ and Rosa Pereira ⁴, ¹University of Sao Paulo, São Paulo, Brazil, ²Univeristy Of Sao Paulo, São Paulo, ³Univeristy Of Sao Paulo, São Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…
Abstract Number: 2872 • 2019 ACR/ARP Annual Meeting
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Ali Yazdanyar¹, Anthony Donato ², Kathleen McElwee ³, Mary Chester Wasko ⁴ and Michael Ward ⁵, ¹Lehigh Valley Hospital- Cedar Crest, Allentown, PA, ²Reading Hospital, PA, Reading, ³Reading Hospital, Reading, PA, ⁴Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁵NIAMS, Bethesda, MD
Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or…
Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Watchareewan Sontichai¹, Daniela Dominguez¹, Lawrence Ng¹, Deborah M. Levy¹, Jonathan Wasserman², Earl Silverman¹ and Linda Hiraki¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…
Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
So Hye Nam¹, Dae-Hee Kim², Doo-Ho Lim³, Ji Seon Oh¹, Seokchan Hong¹, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Cardiology, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…
Abstract Number: 296 • 2018 ACR/ARHP Annual Meeting
Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
Manjari Lahiri^1,2, Peter P.M. Cheung^1,2, Preeti Dhanasekaran², Su Ren Wong³, Ai Yap³, Daphne Tan³, Amelia Santosa^1,2 and Phillip HC Phan², ¹Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Department of Rehabilitation, National University Hospital, Singapore, Singapore, Singapore
Background/Purpose: Quality standards recommend an annual review by a multidisciplinary team (MDT) for all patients with rheumatoid arthritis (RA); however, this is based on expert…
Abstract Number: 1850 • 2018 ACR/ARHP Annual Meeting
A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada
Siok Hoon Lily Lim^1,2, Ruth Ann Marrie³, Okechukwu Ekuma⁴, Marni Brownell⁴, Christine A. Peschken⁵, Carol A Hitchon⁶, Kerstin Gerhold^7,8 and Lisa Lix⁹, ¹Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ²Pediatrics, University of MAnitoba, Winnipeg, MB, Canada, ³Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ⁴Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, ⁵RR 149G, University of Manitoba, Winnipeg, MB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁸Faculty of Health Sciences, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada, ⁹Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Childhood-onset chronic rheumatic diseases (ChildCRD) are rheumatic diseases with onset <18 years old, including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD). ChildCRD…
Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Paul Studenic¹, Gregor Bond², Andreas Kerschbaumer³, Manuel Bécède³, Karel Pavelka⁴, Dmitry Karateev⁵, Jutta Stieger⁶, Rudolf Puchner⁷, Ruediger Mueller⁸, Elisabeth Puchhammer-Stöckl⁹, Martina Durechova¹⁰, Michaela Loiskandl¹⁰, Thomas Perkmann¹¹, Marta Olejarova⁴, Elena Luchikhina¹², Carl-Walter Steiner¹³, Michael Bonelli¹⁰, Josef S. Smolen¹⁴ and Daniel Aletaha¹⁰, ¹Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine 3, Division of Nephrology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, ⁵Department of Rheumatology, Department of Rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ⁶2nd Deparment of Medicine, 2nd Deparment of Medicine, Hitzing Hospital, Vienna, Austria, ⁷Private Office, Wels, Austria, ⁸Division of Rheumatology, Immunology and Rehabilitation, Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Institute for Virology, Institute for Virology, Medical University of Vienna, Vienna, Austria, ¹⁰Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Department of Laboratory Medicine, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ¹²Department of rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ¹³Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…
Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Angel Alberto Herrera Guerra¹, Sampath Prahalad¹, Kelly A. Rouster-Stevens¹, Rouba Garro², Leah Bryan³ and Yin Hong⁴, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pathology, Children's Health Care of Atlanta, Atlanta, GA
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…
Abstract Number: 1882 • 2018 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Haruhito A. Uchida¹, Yoshikazu Nakaoka², Hajime Yoshifuji³, Takahiko Sugihara⁴, Yoshiko Watanabe⁵, Masayoshi Harigai⁶, Yoshihiro Arimura⁷ and Mitsuaki Isobe⁸, ¹Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ³Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁶Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ⁷Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) typically affects young women under 40 years old, whereas patients with onset age over 40 years are occasionally observed. It still…
Abstract Number: 477 • 2018 ACR/ARHP Annual Meeting
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Takayuki Kishi^1,2, Jesse Wilkerson³, Marjo Smith³, Nastaran Bayat¹, Michael Henrickson⁴, Bianca Lang⁵, Murray Passo⁶, Frederick W. Miller¹, Michael Ward⁷ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³Social & Scientific Systems, Inc., Durham, NC, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁶Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Daily oral prednisone has been the main therapy in juvenile dermatomyositis (JDM), and combination therapy with methotrexate (MTX) introduced soon after diagnosis has been…
Abstract Number: 2359 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
Isabela Bertoglio¹, Glaucia Abrahão¹, Eloisa Bonfa² and Michelle Lopes³, ¹Rheumatology, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Now-a-days there is a growing trend of switching to a more patient-centered healthcare system, with a widespread use of patient-reported outcomes (PROs). However, most…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 2406 • 2018 ACR/ARHP Annual Meeting
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
Andreas Reiff, Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Chronic uveitis is a common manifestation of pediatric rheumatologic conditions and may result in irreversible blindness and long term disability. While chronic anterior uveitis…
Abstract Number: 717 • 2018 ACR/ARHP Annual Meeting
The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
Arthur Mageau¹, Jean Francois Timsit¹, Anne Perozziello¹, Stephane Ruckly¹, Claire Dupuis¹, Lila Bouadma¹, Thomas Papo¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Lupus nephritis occurs in about 50% of SLE patients. We aimed to analyze the impact of chronic kidney disease (CKD) on major clinical outcomes…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].